{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:08:44Z","timestamp":1784221724769,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,16]]},"DOI":"10.7759\/cureus.112802","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:02:32Z","timestamp":1784221352000},"source":"Crossref","is-referenced-by-count":0,"title":["A Diagnostic Challenge: Uncovering Autoimmune Hepatitis Masked by Choledocholithiasis and Unsupervised Ivermectin Use"],"prefix":"10.7759","author":[{"given":"Haytham","family":"Alqasmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Jawich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S","family":"Almaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane","family":"Alroshood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed H","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rija","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Tarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wehbi","family":"Hanayni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases","volume":"72","author":"Mack CL","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al.. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020, 72:671-722. 10.1002\/hep.31065","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.017","article-title":"EASL clinical practice guidelines on the management of autoimmune hepatitis","volume":"83","year":"2025","unstructured":"EASL clinical practice guidelines on the management of autoimmune hepatitis. J Hepatol. 2025, 83.453-501. 10.1016\/j.jhep.2025.03.017","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes EM","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al.. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008, 48:169-76. 10.1002\/hep.22322","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41424-018-0028-1","article-title":"Role of age in presentation, response to therapy and outcome of autoimmune hepatitis","volume":"9","author":"Baven-Pronk MA","year":"2018","unstructured":"Baven-Pronk MA, Biewenga M, van Silfhout JJ, et al.. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. Clin Transl Gastroenterol. 2018, 9:165. 10.1038\/s41424-018-0028-1","journal-title":"Clin Transl Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616651092","article-title":"Markedly elevated liver enzymes in choledocholithiasis in the absence of hepatocellular disease: case series and literature review","volume":"4","author":"Tetangco EP","year":"2016","unstructured":"Tetangco EP, Shah N, Arshad HM, Raddawi H. Markedly elevated liver enzymes in choledocholithiasis in the absence of hepatocellular disease: case series and literature review. J Investig Med High Impact Case Rep. 2016, 4:2324709616651092. 10.1177\/2324709616651092","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07981-7","article-title":"Choledocholithiasis can present with marked transaminases elevation: systematic review and meta-analysis","volume":"68","author":"Mohamed MF","year":"2023","unstructured":"Mohamed MF, Elfert K, Wadhavkar N, et al.. Choledocholithiasis can present with marked transaminases elevation: systematic review and meta-analysis. Dig Dis Sci. 2023, 68:3428-35. 10.1007\/s10620-023-07981-7","journal-title":"Dig Dis Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade RJ","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, et al.. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023, 79:853-66. 10.1016\/j.jhep.2023.04.033","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Bj\u00f6rnsson ES","year":"2022","unstructured":"Bj\u00f6rnsson ES, Medina-Caliz I, Andrade RJ, Lucena MI. Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. Hepatol Commun. 2022, 6:1895-909. 10.1002\/hep4.1959","journal-title":"Hepatol Commun"},{"key":"ref9","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.003","article-title":"First case of ivermectin-induced severe hepatitis","volume":"100","author":"Veit O","year":"2006","unstructured":"Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006, 100:795-7. 10.1016\/j.trstmh.2006.02.003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2023.v113i6.624","article-title":"Ivermectin drug induced liver injury","volume":"113","author":"Sonderup M","year":"2023","unstructured":"Sonderup M, Mudini W, Spearman W. Ivermectin drug induced liver injury. S Afr Med J. 2023, 113:24-5. 10.7196\/SAMJ.2023.v113i6.624","journal-title":"S Afr Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3374","article-title":"Autoimmune liver serology: current diagnostic and clinical challenges","volume":"14","author":"Bogdanos DP","year":"2008","unstructured":"Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008, 14:3374-87. 10.3748\/wjg.14.3374","journal-title":"World J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092267","article-title":"Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen\/liver pancreas in autoimmune hepatitis","volume":"9","author":"Zhang WC","year":"2014","unstructured":"Zhang WC, Zhao FR, Chen J, Chen WX. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen\/liver pancreas in autoimmune hepatitis. PLoS One. 2014, 9:e92267. 10.1371\/journal.pone.0092267","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan G","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015, 17:10.3390\/ijms17010014","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14195","article-title":"Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis","volume":"39","author":"Weber S","year":"2019","unstructured":"Weber S, Benesic A, Rotter I, Gerbes AL. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int. 2019, 39:1906-17. 10.1111\/liv.14195","journal-title":"Liver Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100094","article-title":"Features and outcome of AIH patients without elevation of IgG","volume":"2","author":"Hartl J","year":"2020","unstructured":"Hartl J, Miquel R, Zachou K, et al.. Features and outcome of AIH patients without elevation of IgG. JHEP Rep. 2020, 2:100094. 10.1016\/j.jhepr.2020.100094","journal-title":"JHEP Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.22037\/ghfbb.v15i4.2383","article-title":"Hepatic disorders associated with the use of ivermectin for SARS-CoV-2 infection in adults: a pharmacovigilance study in VigiBase","volume":"15","author":"Oscanoa TJ","year":"2022","unstructured":"Oscanoa TJ, Amado J, Romero-Ortuno R, Carvajal A. Hepatic disorders associated with the use of ivermectin for SARS-CoV-2 infection in adults: a pharmacovigilance study in VigiBase. Gastroenterol Hepatol Bed Bench. 2022, 15:426-9. 10.22037\/ghfbb.v15i4.2383","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki A","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al.. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011, 54:931-9. 10.1002\/hep.24481","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503586-a-diagnostic-challenge-uncovering-autoimmune-hepatitis-masked-by-choledocholithiasis-and-unsupervised-ivermectin-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:02:33Z","timestamp":1784221353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503586-a-diagnostic-challenge-uncovering-autoimmune-hepatitis-masked-by-choledocholithiasis-and-unsupervised-ivermectin-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.112802","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}